MX2020009787A - Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis. - Google Patents
Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis.Info
- Publication number
- MX2020009787A MX2020009787A MX2020009787A MX2020009787A MX2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A
- Authority
- MX
- Mexico
- Prior art keywords
- hgfr
- antibody fragment
- extracellular portion
- hgfr antibody
- metastasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000003875A IT201800003875A1 (it) | 2018-03-22 | 2018-03-22 | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| PCT/IB2019/052307 WO2019180658A1 (en) | 2018-03-22 | 2019-03-21 | Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009787A true MX2020009787A (es) | 2020-11-09 |
Family
ID=62530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009787A MX2020009787A (es) | 2018-03-22 | 2019-03-21 | Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11814433B2 (OSRAM) |
| EP (1) | EP3768710A1 (OSRAM) |
| JP (1) | JP7381555B2 (OSRAM) |
| KR (1) | KR20200135449A (OSRAM) |
| CN (1) | CN112041340A (OSRAM) |
| AU (1) | AU2019240274B2 (OSRAM) |
| BR (1) | BR112020018981A8 (OSRAM) |
| CA (1) | CA3093513A1 (OSRAM) |
| IL (1) | IL277476B2 (OSRAM) |
| IT (1) | IT201800003875A1 (OSRAM) |
| MX (1) | MX2020009787A (OSRAM) |
| SG (1) | SG11202008612XA (OSRAM) |
| WO (1) | WO2019180658A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3413363B1 (en) * | 2016-02-02 | 2021-03-24 | National Institute for Materials Science | Ferromagnetic tunnel junction, magnetoresistive effect element and spintronics device in which said ferromagnetic tunnel junction is used, and method of manufacturing ferromagnetic tunnel junction |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025188676A1 (en) * | 2024-03-04 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of cells for secretion of therapeutic antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0619424B1 (pt) * | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| BRPI0707480A8 (pt) * | 2006-02-06 | 2022-11-08 | Vertical Bio Ag | Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos |
| CN101914161B (zh) * | 2010-08-13 | 2013-12-11 | 四川大学 | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
-
2018
- 2018-03-22 IT IT102018000003875A patent/IT201800003875A1/it unknown
-
2019
- 2019-03-21 SG SG11202008612XA patent/SG11202008612XA/en unknown
- 2019-03-21 WO PCT/IB2019/052307 patent/WO2019180658A1/en not_active Ceased
- 2019-03-21 IL IL277476A patent/IL277476B2/en unknown
- 2019-03-21 MX MX2020009787A patent/MX2020009787A/es unknown
- 2019-03-21 AU AU2019240274A patent/AU2019240274B2/en active Active
- 2019-03-21 US US16/982,330 patent/US11814433B2/en active Active
- 2019-03-21 CA CA3093513A patent/CA3093513A1/en active Pending
- 2019-03-21 KR KR1020207030214A patent/KR20200135449A/ko active Pending
- 2019-03-21 JP JP2021500367A patent/JP7381555B2/ja active Active
- 2019-03-21 EP EP19721054.5A patent/EP3768710A1/en active Pending
- 2019-03-21 BR BR112020018981A patent/BR112020018981A8/pt unknown
- 2019-03-21 CN CN201980020753.XA patent/CN112041340A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020018981A2 (pt) | 2021-01-05 |
| US20210070868A1 (en) | 2021-03-11 |
| JP7381555B2 (ja) | 2023-11-15 |
| WO2019180658A1 (en) | 2019-09-26 |
| IL277476A (en) | 2020-11-30 |
| US11814433B2 (en) | 2023-11-14 |
| CA3093513A1 (en) | 2019-09-26 |
| AU2019240274B2 (en) | 2025-04-24 |
| CN112041340A (zh) | 2020-12-04 |
| IL277476B1 (en) | 2026-01-01 |
| JP2021518170A (ja) | 2021-08-02 |
| RU2020129465A (ru) | 2022-04-22 |
| AU2019240274A1 (en) | 2020-10-15 |
| BR112020018981A8 (pt) | 2022-06-28 |
| KR20200135449A (ko) | 2020-12-02 |
| IL277476B2 (en) | 2026-05-01 |
| IT201800003875A1 (it) | 2019-09-22 |
| EP3768710A1 (en) | 2021-01-27 |
| SG11202008612XA (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003728A1 (es) | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000) | |
| CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| BR112014028941A2 (pt) | combinação de terapia envolvendo anticorpos contra claudin 18.2 para o tratamento de câncer | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| BR112014028948A2 (pt) | combinação de terapia envolvendo anticorpos contra claudin 18.2 para o tratamento de câncer | |
| MX360497B (es) | Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos. | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| BR112017015627A2 (pt) | Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm) | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| CO6571892A2 (es) | Composiciones y métodos para el diagnostico y tratamiento de tumores | |
| DOP2017000248A (es) | PROTEÍNA DE UNIÓN A RGMa Y SU USO | |
| MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
| ECSP20076576A (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| MX2021008131A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2019005491A (es) | Anticuerpo que enlaza especificamente a cd66c y uso del mismo. | |
| CY1126559T1 (el) | Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: VERTICAL BIO AG |